Structure Therapeutics Is Bracing for Copycat Weight-Loss Pills

Structure Therapeutics Inc.’s experimental weight-loss pill hasn’t been approved yet, but the company is already worried about copycat versions flooding the market.

“It’s the thing I fear the most,” Structure Chief Executive Officer Raymond Stevens said in an interview at the JPMorgan Healthcare Conference in San Francisco on Wednesday. “We’ve really got to get this compounding issue under control.”